Live Webinar

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Hosted by AJMC, Managed Healthcare Executive, Pharmacy Times and PBMI

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
  • News
  • Watch
  • Journals
  • Conferences
  • Events
  • Resources
  • CE
  • About AJMC
  • Subscribe
Opinion|Videos|July 29, 2024

Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

Episodes in this series

Video content above is prompted by the following:

  • How do mutations associated like STK11, KEAP1, KRAS impact effectiveness of standard therapies and confer resistance? 

  • In real-world clinical practice, how frequently do patients with mNSCLC undergo comprehensive molecular and biomarker testing through techniques like NGS to evaluate for genetic alterations and potential targetable mutations?

Related Content